Video Library
Brief, informative videos on clinical science and patient counseling topics pertaining to analgesic use. Helpful for all patient-care professionals in your practice.
 |
Acetaminophen & NSAIDs: MOAs and Clinical Considerations (Abridged) |
|
Scientific animation shows how the Mechanisms of Action (MOAs) of acetaminophen and NSAIDs can have important implications for patient care. Introduction by pain specialist Bruce D. Nicholson, MD. |
|
 |
|
|
Ibuprofen may compete with aspirin to occupy COX-1 receptors, potentially compromising aspirin’s cardiovascular benefits.1 (Excerpt) |
|
 |
|
|
NSAID inhibition of COX-1 can diminish the COX-1 mediated role in gastric mucosal protection, which can lead to GI side effects such as irritation and bleeding.2-5 (Excerpt) |
|
 |
|
|
In kidneys with some degree of dysfunction, NSAID inhibition of COX-1 and COX-2 can further compromise renal function.6 (Excerpt) |
|
 |
Acetaminophen & NSAIDs: MOAs and Clinical Considerations (Unabridged) |
|
Scientific animation demonstrates the clinical implications of the Mechanisms of Action (MOAs); commentary explores how to counsel patients on their selection and use of OTC analgesics. |
|
 |
|
|
Clinical rationales and counseling messages for promoting patients' proper use of acetaminophen and other OTC analgesics. (Excerpt) |
|
 |
|
|
For over 20 years, the makers of TYLENOL® have supported students pursuing degrees in healthcare by awarding a total of $250,000 in scholarships each year to forty exceptional students. Learn more from Meghan, a medical student and 2011 scholarship recipient. |
|
|
References: 1. Catella-Lawson F, Reilly MP, Kapoor SC, Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. American College of Cardiology. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;1894-1909. 3. Hirschowitz BI. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Gastroenterol. 1994;2(3):207-223. 4. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 5. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21(6):992-1003. 6. DeMaria AN, Weir MR. Coxibs—beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage. 2003;25(2S):S41-S49. |
|